ARRANGED AS TO MOST RECENT DEVELOPMENTS:

 

Contrasting Effects of Low Dose IL-2 on Vaccine Boosted Simian Immunodeficiency Virus (SIV) Specific CD4+ and CD8+ T Cells in Macaques Chronically Infected with SIVmac251

         Journal of Immunology, February 15, 2005   

The Quantal Theory of How the Immune System Discriminates Between "Self and Non-Self"

        http://www.medimmunol.com/content/pdf/1476-9433-3-3.pdf

Numedx article: “New paradigms in HIV therapy: Boosting_HIV_ Immunity”

Numedex_NEW PARADIGMS_IN_HIV_THERAPY_final.pdf

Commentary: The HIV vaccine Saga

        http://www.medimmunol.com/content/2/1/1

Commentary: Optimal Clinical Trial Design for Immune-Based Therapies in Chronic Viral Infections

         http://www.medimmunol.com/content/1/1/4

A New Journal, Medical Immunology, is now On-Line

http://www.medimmunol.com

Hepatitis C Virus Infection: Why it is Such a Growing Problem

Notes from Kendall A. Smith, August 2002

Report from Barcelona-IV International AIDS Congress

Notes from Kendall A. Smith, July, 2002

Towards a Cure of Chronic HIV Infection: Can HIV Vaccines and Interleukin 2 Help Promote Immunity to HIV?

Notes from Kendall A. Smith, June 12, 2002

Frequently Asked Questions Concerning Immunotherapy Clinical Trials

ALVAC / IL2 Clinical Trial Frequently Asked Questions

Highlights from the 8th Conference on Retroviruses & Opportunistic Infections February 4-8, 2001

Notes from Kendall A. Smith

What is Therapeutic Vaccination?

Essay on Therapeutic Immunization: Principles & Practice-January 24, 2001

Designing Clinical Trials for Immune-Based Therapies

Commentary for The AIDS Reader-in press, January, 2001

Current IL2 Clinical Trials Enrolling Subjects

Cornell Trial of Immune-Based Therapies: Low Dose Daily IL2 & Canarypox HIV Vaccine

Protocol (PDF File)

Consent Form (PDF File)

Essay on IL2 Toxicities

December 24, 2000, Follow-up of Essay on Low Dose IL2 Therapy

Summary of Workshop on Immune Based Therapies & HIV Disease-

The Forum for Collaborative HIV Research, December 7-8, 2000

Low Dose Daily IL2 Therapy vs. High Dose Intermittent IL2 Therapy

Essay by Kendall A. Smith, January 12, 2001, edited from December 24, 2000

8th Annual Conference on Retroviruses & Opportunistic Infections, Chicago, ILL, February 4-8, 2001

Abstract # B75e-In Vivo Assessment of Antiviral Reactivity in Chronic HIV Infection (PDF file)

Weill Cornell Studies Reveal Accelerated Improvement of Immune System & Antiviral Reactivity in Chronic HIV Infection: Low Daily Doses of Interleukin 2 May Hold Key to Management of HIV Infection

Cornell Press Release, November 13, 2000

New Results in Vaccine + IL2 Studies in Macaques

Report in Nature, October 20, 2000

Therapeutic Vaccination of Macaques Treated with HAART

Nature Medicine, October 2000

Immunologic Control of HIV Infection in Acute Infection

Nature, September 28, 2000

IL-2 Low Dose and Treatment Interruption: Interview with Kendall A. Smith, M.D.

Weill Cornell Researchers Develop New Treatment for HIV-Positive Patients